Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 8
2003 7
2004 3
2005 6
2006 10
2007 17
2008 8
2009 11
2010 20
2011 27
2012 24
2013 28
2014 34
2015 40
2016 27
2017 35
2018 33
2019 20
2020 31
2021 33
2022 26
2023 31
2024 24
2025 23
2026 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

466 results

Results by year

Filters applied: . Clear all
Page 1
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.
Sangro B, Kudo M, Erinjeri JP, Qin S, Ren Z, Chan SL, Arai Y, Heo J, Mai A, Escobar J, Lopez Chuken YA, Yoon JH, Tak WY, Breder VV, Suttichaimongkol T, Bouattour M, Lin SM, Peron JM, Nguyen QT, Yan L, Chiu CF, Santos FA, Veluvolu A, Thungappa SC, Matos M, Żotkiewicz M, Udoye SI, Kurland JF, Cohen GJ, Lencioni R; EMERALD-1 Investigators. Sangro B, et al. Among authors: yoon jh. Lancet. 2025 Jan 18;405(10474):216-232. doi: 10.1016/S0140-6736(24)02551-0. Epub 2025 Jan 8. Lancet. 2025. PMID: 39798579 Free PMC article. Clinical Trial.
GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma.
Kim HS, Yoon JH, Choi JY, Yoon MG, Baek GO, Kang M, Jang SH, Park W, Go Y, Ng JT, Nam SW, Jeong JY, Han JE, Cho HJ, Lim SB, Kim SS, Cheong JY, Eun JW. Kim HS, et al. Among authors: yoon jh. Clin Mol Hepatol. 2025 Jul;31(3):914-934. doi: 10.3350/cmh.2024.1038. Epub 2025 Feb 6. Clin Mol Hepatol. 2025. PMID: 39914372 Free PMC article.
Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial.
Yuen MF, Heo J, Jang JW, Yoon JH, Kweon YO, Park SJ, Tami Y, You S, Yates P, Tao Y, Cremer J, Campbell F, Elston R, Theodore D, Paff M, Bennett CF, Kwoh TJ. Yuen MF, et al. Among authors: yoon jh. Nat Med. 2021 Oct;27(10):1725-1734. doi: 10.1038/s41591-021-01513-4. Epub 2021 Oct 12. Nat Med. 2021. PMID: 34642494 Free PMC article. Clinical Trial.
Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial.
Yuen MF, Asselah T, Jacobson IM, Brunetto MR, Janssen HLA, Takehara T, Hou JL, Kakuda TN, Lambrecht T, Beumont M, Kalmeijer R, Guinard-Azadian C, Mayer C, Jezorwski J, Verbinnen T, Lenz O, Shukla U, Biermer M; REEF-1 Study Group. Yuen MF, et al. Lancet Gastroenterol Hepatol. 2023 Sep;8(9):790-802. doi: 10.1016/S2468-1253(23)00148-6. Epub 2023 Jul 10. Lancet Gastroenterol Hepatol. 2023. PMID: 37442152 Clinical Trial.
AI model using CT-based imaging biomarkers to predict hepatocellular carcinoma in patients with chronic hepatitis B.
Shin H, Hur MH, Song BG, Park SY, Kim GA, Choi G, Nam JY, Kim MA, Park Y, Ko Y, Park J, Lee HA, Chung SW, Choi NR, Park MK, Lee YB, Sinn DH, Kim SU, Kim HY, Kim JM, Park SJ, Lee HC, Lee DH, Chung JW, Kim YJ, Yoon JH, Lee JH. Shin H, et al. Among authors: yoon jh. J Hepatol. 2025 Jun;82(6):1080-1088. doi: 10.1016/j.jhep.2024.12.029. Epub 2024 Dec 20. J Hepatol. 2025. PMID: 39710148
466 results